Overview

Intellect Neurosciences, Inc. (OTCQB: ILNS)

Intellect Neurosciences, Inc. is a Manhattan-based biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders. The Company's drug product pipeline includes OX1, which has been tested in Phase 1 clinical trials; IN-N01, a humanized monoclonal antibody designed to promote the clearance of soluble amyloid beta; and RECALL-VAX, a vaccine technology that has the potential to delay or prevent Alzheimer's disease in people who are at risk.

Upcoming Event

Seventh Annual Neurotech Investing and Partnering Conference
May 21, 2012

Quick Links


Corporate Presentation	All SEC Filings

Share Statistics

Outstanding: 95,311,449 as of May 7, 2012

Management Team

Daniel G. Chain, Ph.D.
Chief Executive Officer and Chairman

Elliot M. Maza
Chief Financial Officer

Investor Relations

Intellect Neurosciences, Inc.
Elliot Maza, JD, CPA, President and Chief Financial Officer
212-448-9300
elliot.maza@intellectns.com
45 West 36th St., 3rd Floor
New York, NY 10018, USA

Transfer Agent

Empire Stock Transfer Inc.
1859 Whitney Mesa Dr.
Henderson, NV 89014

Auditors

Paritz and Company, P.A.